SERUM FREE LIGHT CHAIN RATIO AND ITS CORRELATION WITH MARKERS OF TUMOR BURDEN AND PROGNOSIS AT INITIAL DIAGNOSIS OF MULTIPLE MYELOMA
Keywords:
serum free light chain ratioAbstract
Multiple myeloma is the most frequent malignant monoclonal gammopathy characterized by plasma cell proliferation and monoclonal M-protein production as consequence. Gold standard for diagnosis of monoclonal gammopathies are urinary and serum electrophoretic tehniques. Until recently, multiple myeloma was defined and diagnosed by damaged organs, particularly through hypercalcemia, renal failure, anemia and bone lesions. International Myeloma Working Group revised the criteria for multiple myeloma diagnosis by adding three biomarkers of malignancy effective in early recognition of patients who have not developed permanent organ damage. Those biomarkers are clonal proliferation of plasmocytes in bone marrow ≥60%, ratio of serum free light chains ≥100 with the included serum free light chain having an absolute concentration >100 mg/L and more than one osseus change on magnetic resonance imaging. This enables early beginning of an effective therapy in high-risk patients. Objective of the research was to evaluate the impact of serum free light chain ratio, total proteins and serum protein electrophoresis, as an initial panel for diagnosis of multiple myeloma, on beta 2 microglobulin and albumin, as markers of tumor burden and prognosis, at baseline and the differences between analyzed parameters in study and control group. Design of the research was a cross sectional study/study of prevalence conducted in the period of two months. Study group consisted of 7 newly diagnosed patients, before treatment, at 18 to 80 years of age. Control group consisted of 10 healthy individuals. All participants were included in the research after prior written informed consent. The concentration of serum free light chains (N-Latex Free Light Chains) and beta 2 microglobulin were determined nephelometrically on the plasma protein analyzer BN proSpec-Siemens (Siemens Medical Systems). The ratio was calculated by the analyzer software. Any result of the ratio <0.26 and >1.65 was considered pathological, depending on the involved component. Significance was determined at p<0.05. Electrophoretic examination of serum proteins was performed by gradient (4-22%) sodium dodecyl sulfate polyacrylamide gel electrophoresis. The confirmation of the diagnosis was obtained from the hospital information system of the Hematology Clinic in Skopje. For R = 0,99 and p<0,01 we found a high correlation between beta 2 microglobulin and serum free light chain ratio, total proteins and serum protein electrophoresis at baseline. For R = 0,98 and p<0,05 there was a high correlation between albumin and serum free light chain ratio, total proteins and protein electrophoresis in serum at baseline. Serum free light chain ratio results were significantly higher in study group p<0,05 (p=0,01). Beta 2 microglobulin results were significantly higher in study group p<0,01 (p=0,001). In conclusion, the results of the study confirmed the association between serum free light chain ratio and beta 2 microglobulin as an indicator of tumor burden in multiple myeloma, as well as with the biological characteristics of myeloma cells.
References
Argyropoulos, C. P., Chen, S. S., Ng, Y. H., Roumelioti, M. E., Shaffi, K., Singh, P. P., & Tzamaloukas, A. H. (2017). Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases. Frontiers in medicine, 4, 73. https://doi.org/10.3389/fmed.2017.00073
Assounga A. G. (2021). Beta 2 microglobulin in kidney failure: A review and an algorithm for renal replacement therapy. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 32(5), 1214–1220. https://doi.org/10.4103/1319-2442.344740
Bataille, R., Grenier, J., & Sany, J. (1984). Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients. Blood, 63(2), 468–476.
Bradwell, A. R., Carr-Smith, H. D., Mead, G. P., Harvey, T. C., & Drayson, M. T. (2003). Serum test for assessment of patients with Bence Jones myeloma. Lancet (London, England), 361(9356), 489–491. https://doi.org/10.1016/S0140-6736(03)12457-9
Cai, Y., Zhao, Y., Dai, Q., Xu, M., Xu, X., & Xia, W. (2021). Prognostic value of the albumin-globulin ratio and albumin-globulin score in patients with multiple myeloma. The Journal of international medical research, 49(3), 300060521997736. https://doi.org/10.1177/0300060521997736
De Novellis, D.; Fontana, R.; Carobene, A.; Serio, B.; Ferrara, I.; Martorelli, M.C.; Mettivier, L.; Guariglia, R.; Luponio, S.; Ruggiero, I.; et al. (2022). Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study. Biomedicines , 10, 1657. https://doi.org/10.3390/biomedicines10071657
International Myeloma Working Group (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British journal of haematology, 121(5), 749–757.
Katzmann, J. A., Kyle, R. A., Benson, J., Larson, D. R., Snyder, M. R., Lust, J. A., Rajkumar, S. V., & Dispenzieri, A. (2009). Screening panels for detection of monoclonal gammopathies. Clinical chemistry, 55(8), 1517–1522. https://doi.org/10.1373/clinchem.2009.126664
Kyle, R. A. (1999). Sequence of testing for monoclonal gammopathies. Archives of pathology & laboratory medicine, 123(2), 114–118. https://doi.org/10.5858/1999-123-0114-SOTFMG
Kyrtsonis, M. C., Vassilakopoulos, T. P., Kafasi, N., Sachanas, S., Tzenou, T., Papadogiannis, A., Galanis, Z., Kalpadakis, C., Dimou, M., Kyriakou, E., Angelopoulou, M. K., Dimopoulou, M. N., Siakantaris, M. P., Dimitriadou, E. M., Kokoris, S. I., Panayiotidis, P., & Pangalis, G. A. (2007). Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. British journal of haematology, 137(3), 240–243. https://doi.org/10.1111/j.1365-2141.2007.06561.x
Mead, G. P., Carr-Smith, H. D., Drayson, M. T., Morgan, G. J., Child, J. A., & Bradwell, A. R. (2004). Serum free light chains for monitoring multiple myeloma. British journal of haematology, 126(3), 348–354. https://doi.org/10.1111/j.1365-2141.2004.05045.x
Oliveros Conejero, R., Pascual Usandizaga, P. & Garrido Chércoles, A. (2020). Optimization of workflow and screening panels for the detection of malignant monoclonal gammopathies. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio, 1(3), 20200042. https://doi.org/10.1515/almed-2020-0042
Pika, T., Minarik, J., Schneiderka, P., Budikova, M., Langova, K., Lochman, P., Bacovsky, J., Farbiakova, V., & Scudla, V. (2008). The correlation of serum immunoglobulin free light chain levels and selected biological markers in multiple myeloma. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 152(1), 61–64. https://doi.org/10.5507/bp.2008.009
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M. V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., Landgren, O., Paiva, B., Dispenzieri, A., Weiss, B., LeLeu, X., Zweegman, S., Lonial, S., Rosinol, L., Zamagni, E., Jagannath, S., … Miguel, J. F. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet. Oncology, 15(12), e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5
Sthaneshwar, P., Nadarajan, V., Maniam, J. A., Nordin, N., & Gin Gin, G. (2009). Serum free light chains: diagnostic and prognostic value in multiple myeloma. Clinical chemistry and laboratory medicine, 47(9), 1101–1107. https://doi.org/10.1515/CCLM.2009.260
Wallington-Beddoe, C. T., & Mynott, R. L. (2021). Prognostic and predictive biomarker developments in multiple myeloma. Journal of hematology & oncology, 14(1), 151. https://doi.org/10.1186/s13045-021-01162-7
Willrich, M. A., & Katzmann, J. A. (2016). Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clinical chemistry and laboratory medicine, 54(6), 907–919. https://doi.org/10.1515/cclm-2015-0580
